FXYD6

Across TCGA pan-cancer cohorts, FXYD6 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FXYD6 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher FXYD6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FXYD6 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LSCC and OV are the cancer types where FXYD6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.809	0.347	.008	16	view →
OV	DFS	Median	All	0.535	1.000	.045	8	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

FXYD6–LSCC (DFS)

Open the LSCC breakdown →